Bristol-Myers Squibb Company (BMS)

Core Business

Bristol Myers Squibb is a leading cell therapy company with two FDA-approved CAR-T products. Breyanzi has emerged as a blockbuster with $1.36 billion in 2025 sales, while Abecma targets multiple myeloma with $427 million in revenue. BMS has invested heavily in next-generation capabilities, including the Orbital Therapeutics acquisition for RNA engineering platforms and a major European manufacturing expansion in Leiden, Netherlands.

Global Presence

Headquartered in Princeton, New Jersey, BMS operates in over 50 countries with 34,000 employees. Its cell therapy manufacturing network includes a 244,000-square-foot facility in Devens, Massachusetts, plus sites in Bothell (WA), Summit (NJ), and Leiden, Netherlands — providing multi-continent production redundancy and capacity to serve thousands of patients annually.

Key Strengths

BMS demonstrates exceptional commercial execution with Breyanzi's rapid growth trajectory, combined with strategic M&A and manufacturing investment totaling billions of dollars. The FDA REMS removal for its CAR-T products in 2025 significantly expanded community hospital access, while the company's diversified portfolio provides financial stability for continued CGT investment.

VerityRank Score

Bristol Myers Squibb achieves a VerityRank Score of 94/100, reflecting its strong dual-product CAR-T franchise, significant manufacturing investment, and proven ability to execute complex cell therapy commercialization.